216 related articles for article (PubMed ID: 20699436)
1. The vascular targeting agent combretastatin-A4 and a novel cis-Restricted {beta}-Lactam Analogue, CA-432, induce apoptosis in human chronic myeloid leukemia cells and ex vivo patient samples including those displaying multidrug resistance.
Greene LM; Nathwani SM; Bright SA; Fayne D; Croke A; Gagliardi M; McElligott AM; O'Connor L; Carr M; Keely NO; O'Boyle NM; Carroll P; Sarkadi B; Conneally E; Lloyd DG; Lawler M; Meegan MJ; Zisterer DM
J Pharmacol Exp Ther; 2010 Nov; 335(2):302-13. PubMed ID: 20699436
[TBL] [Abstract][Full Text] [Related]
2. Novel cis-restricted β-lactam combretastatin A-4 analogues display anti-vascular and anti-metastatic properties in vitro.
Nathwani SM; Hughes L; Greene LM; Carr M; O'Boyle NM; McDonnell S; Meegan MJ; Zisterer DM
Oncol Rep; 2013 Feb; 29(2):585-94. PubMed ID: 23232969
[TBL] [Abstract][Full Text] [Related]
3. BubR1 is required for the mitotic block induced by combretastatin-A4 and a novel cis-restricted ß-lactam analogue in human cancer cells.
Greene LM; Carr M; Keeley NO; Lawler M; Meegan MJ; Zisterer DM
Int J Mol Med; 2011 May; 27(5):715-23. PubMed ID: 21369694
[TBL] [Abstract][Full Text] [Related]
4. Lead identification of conformationally restricted β-lactam type combretastatin analogues: synthesis, antiproliferative activity and tubulin targeting effects.
Carr M; Greene LM; Knox AJ; Lloyd DG; Zisterer DM; Meegan MJ
Eur J Med Chem; 2010 Dec; 45(12):5752-66. PubMed ID: 20933304
[TBL] [Abstract][Full Text] [Related]
5. STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells.
Greene LM; Kelly L; Onnis V; Campiani G; Lawler M; Williams DC; Zisterer DM
J Pharmacol Exp Ther; 2007 Apr; 321(1):288-97. PubMed ID: 17202400
[TBL] [Abstract][Full Text] [Related]
6. Combretastatin CA-4 and combretastatin derivative induce mitotic catastrophe dependent on spindle checkpoint and caspase-3 activation in non-small cell lung cancer cells.
Vitale I; Antoccia A; Cenciarelli C; Crateri P; Meschini S; Arancia G; Pisano C; Tanzarella C
Apoptosis; 2007 Jan; 12(1):155-66. PubMed ID: 17143747
[TBL] [Abstract][Full Text] [Related]
7. Combretazet-3 a novel synthetic cis-stable combretastatin A-4-azetidinone hybrid with enhanced stability and therapeutic efficacy in colon cancer.
Greene LM; Wang S; O'Boyle NM; Bright SA; Reid JE; Kelly P; Meegan MJ; Zisterer DM
Oncol Rep; 2013 Jun; 29(6):2451-8. PubMed ID: 23564200
[TBL] [Abstract][Full Text] [Related]
8. β-Lactam analogues of combretastatin A-4 prevent metabolic inactivation by glucuronidation in chemoresistant HT-29 colon cancer cells.
Malebari AM; Greene LM; Nathwani SM; Fayne D; O'Boyle NM; Wang S; Twamley B; Zisterer DM; Meegan MJ
Eur J Med Chem; 2017 Apr; 130():261-285. PubMed ID: 28254699
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, evaluation and structural studies of antiproliferative tubulin-targeting azetidin-2-ones.
O'Boyle NM; Greene LM; Bergin O; Fichet JB; McCabe T; Lloyd DG; Zisterer DM; Meegan MJ
Bioorg Med Chem; 2011 Apr; 19(7):2306-25. PubMed ID: 21397510
[TBL] [Abstract][Full Text] [Related]
10. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of azetidinone analogues of combretastatin A-4 as tubulin targeting agents.
O'Boyle NM; Carr M; Greene LM; Bergin O; Nathwani SM; McCabe T; Lloyd DG; Zisterer DM; Meegan MJ
J Med Chem; 2010 Dec; 53(24):8569-84. PubMed ID: 21080725
[TBL] [Abstract][Full Text] [Related]
12. Antimultidrug-resistant effect and mechanism of a novel CA-4 analogue MZ3 on leukemia cells.
Xu D; Fang L; Zhu Q; Hu Y; He Q; Yang B
Pharmazie; 2008 Jul; 63(7):528-33. PubMed ID: 18717489
[TBL] [Abstract][Full Text] [Related]
13. β-Lactams with antiproliferative and antiapoptotic activity in breast and chemoresistant colon cancer cells.
Malebari AM; Fayne D; Nathwani SM; O'Connell F; Noorani S; Twamley B; O'Boyle NM; O'Sullivan J; Zisterer DM; Meegan MJ
Eur J Med Chem; 2020 Mar; 189():112050. PubMed ID: 31954879
[TBL] [Abstract][Full Text] [Related]
14. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo.
Wong VK; Chiu P; Chung SS; Chow LM; Zhao YZ; Yang BB; Ko BC
Clin Cancer Res; 2005 Aug; 11(16):6002-11. PubMed ID: 16115945
[TBL] [Abstract][Full Text] [Related]
15. 4,5-Diaryl-3-aminopyrazole derivatives as analogs of Combretastatin A-4: synthesis and biological evaluation.
Liu T; Cui R; Chen J; Zhang J; He Q; Yang B; Hu Y
Arch Pharm (Weinheim); 2011 May; 344(5):279-86. PubMed ID: 21290430
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and anticancer properties of 5-arylbenzoxepins as conformationally restricted isocombretastatin A-4 analogs.
Rasolofonjatovo E; Provot O; Hamze A; Rodrigo J; Bignon J; Wdzieczak-Bakala J; Lenoir C; Desravines D; Dubois J; Brion JD; Alami M
Eur J Med Chem; 2013 Apr; 62():28-39. PubMed ID: 23353744
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, biological evaluation and cocrystal structures with tubulin of chiral β-lactam bridged combretastatin A-4 analogues as potent antitumor agents.
Zhou P; Liang Y; Zhang H; Jiang H; Feng K; Xu P; Wang J; Wang X; Ding K; Luo C; Liu M; Wang Y
Eur J Med Chem; 2018 Jan; 144():817-842. PubMed ID: 29306206
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, biochemical and molecular modelling studies of antiproliferative azetidinones causing microtubule disruption and mitotic catastrophe.
O'Boyle NM; Carr M; Greene LM; Keely NO; Knox AJ; McCabe T; Lloyd DG; Zisterer DM; Meegan MJ
Eur J Med Chem; 2011 Sep; 46(9):4595-607. PubMed ID: 21840628
[TBL] [Abstract][Full Text] [Related]
19. PSC 833 induces apoptosis in drug-sensitive human leukemia cell line and modulates resistance to paclitaxel in its multidrug-resistant variant.
Duraj J; Takacsova X; Sedlak J; Sulikova M; Hunakova L; Bies J; Chorvath B
Anticancer Res; 2000; 20(6B):4627-32. PubMed ID: 11205313
[TBL] [Abstract][Full Text] [Related]
20. Effects of the multidrug resistance modulator HZ08 on the apoptosis pathway in human chronic leukaemia cell line K562/A02.
Cen J; Zhu YL; Yang Y; Zhu JR; Fang WR; Huang WL; Li YM; Tao YF
Arzneimittelforschung; 2011; 61(11):622-30. PubMed ID: 22232851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
